This cooking tutorial provides step-by-step instructions on how to elevate three traditional BBQ side dishes—green beans, ...

Ahead of launching its first Android XR product, “Project Aura,” the new XREAL 1S glasses deliver some impressive new display upgrades, and for a lower price than its predecessor too. The XREAL 1S is ...

Posts from this topic will be added to your daily email digest and your homepage feed. Despite the spec bump, the Xreal 1S are $50 cheaper than their predecessor. Despite the spec bump, the Xreal 1S ...

If you’re looking for a simple, sweet treat to gift friends or family this holiday season, homemade peanut brittle is an easy win. The recipe is so straightforward you may not even need a trip to the ...

Share on Pinterest The TrumpRx prescription drug savings program is expected to be available by early 2026. Eli Lilly and Novo Nordisk have agreed to sell their weight-loss drugs, Wegovy and Zepbound, ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Dothée is a writer in Los Angeles. On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested ...

It's no secret that triple-A game development is becoming unsustainably expensive, so to support major titles, big studios should look to diversify the scale of their productions. That's according to ...

Of all the possible side effects that come with taking a GLP-1, losing your hair is perhaps one of the scariest. The good news is this hair loss is typically temporary and will resolve over time. To ...

The explosive rise of GLP-1 medications—such as Mounjaro, Ozempic, and Wegovy—has ignited more than just headlines. It has fundamentally shifted how Americans access and pay for medications, driving ...

Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...